Chem. J. Chinese Universities

• 研究快报 • Previous Articles     Next Articles

Bioactivity and Structure of Analogues of Exendin-4

SONG Xiang-Wei1, WANG Xue-Li2, XIONG Xin-Hui1, NIU Jian-Li1 , WANG Shi-Qing3, WANG Li-Ping1*, LI Wei1   

    1. College of Life Science, Jilin University,
    2. Key Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, Jilin University, Changchun 130021, China;
    3. School of Biological and Agricultural Engineering, Jilin University, Changchun 130022, China
  • Received:2007-12-06 Revised:1900-01-01 Online:2008-06-10 Published:2008-06-10
  • Contact: WANG Li-Ping

Abstract: Exendin-4 is an incretin mimetic that has been studied as a potent drug for the treatment of the type 2 diabetes. To screen the shorter analogues of Exendin-4 that have the same bioactivity, we designed two analogues of Exendin-4: Ex1, deleting this sequence and Ex2, replacing this sequence with three Alas. The proliferation assay of RINm-5F cell using MTT suggested the bioactivity of Ex1 and Ex2 was lower compared to that of Exendin-4 caused by the deletion of LSKQMEEEA. Ex1 and Ex2 had the same strong stability against DPPⅣ with Exendin-4. CD data suggested the helix content of Ex1 had a significant lost, but the helix content of Ex2 was the same as that of Exendin-4. The emission maximum of Ex1 was red-shifted of 3 nm relative to Exendin-4, the absence of this sequence made Trp25 more apt to hydrophilic and the Trp-cage became looser. So we have designed Ex2, the mimetic of Exendin-4 that had the same bioactivity and strong stability against DPPⅣ with Exendin-4 successfully. It became a solid foundation for designing shorter analogues of Exendin-4 for oral drug of diabetes.

Key words: Exendin-4 analogue, Helix structure, Stability, Bioactivity

CLC Number: 

TrendMD: